Headline–confidence gap
Headline confirmed
Management confidence reinforces the reported beat.
ABBV · Q3 2026
AbbVie Inc.
51EarnIQ signal
↗
Confidence rising
Mild quarter-over-quarter shiftStrong portfolio growth powers robust revenue gains, offsetting acquisition dilution and supporting long-term momentum.
- ✓Guidance was lowered, with high specificity.
- ✓Management tone registered as confident (85/100).
- ✓EarnIQ detected 0 potential management deflections.
EPS: reported vs expected-0.7%$3.65 vs $3.68
Revenue: reported vs expected-0.7%$17.0B vs $17.1B
Guidance specificityHighLowered
Market expectations supplied by Finnhub · Reported vs consensus estimate
Based on our substantial momentum, AbbVie's long-term outlook remains very strong.
Premium intelligence
The evidence behind the signal
Management language
Why confidence moved
“AbbVie delivered another excellent quarter, marked by outstanding execution and pipeline advancement.”
“We also announced the proposed acquisition of Apogee Therapeutics, which strengthens our ability to deliver innovative medicines to patients, bolsters our immunology leadership and creates significant shareholder value”
“Based on our substantial momentum, AbbVie's long-term outlook remains very strong.”
Guidance specificity
90/100
High specificity
AbbVie updated its full-year 2026 adjusted diluted EPS guidance range to $13.87 - $14.07, incorporating a $0.14 dilutive impact from the proposed Apogee Therapeutics acquisition offset by $0.10 of overperformance.
Pressure point
Risks related to the proposed
0 potential deflections detected in management communication.
Narrative break
What changed
Deepening immunology portfolio and expanding biologics pipeline through the proposed acquisition of Apogee Therapeutics.
Q&A evidence
Management responses
No material Q&A deflections were detected.
Key positives
- Global immunology net revenues increased 15.1 percent led by strong growth from Skyrizi and Rinvoq.
- Global neuroscience net revenues increased 20.3 percent driven by strong performances across Vraylar, Botox Therapeutic, and migraine therapies.
- Definitive agreement to acquire Apogee Therapeutics, enhancing the immunology pipeline with mega-blockbuster peak sales potential assets.
Key risks
- Risks related to the proposed acquisition of Apogee Therapeutics, including potential failure to consummate on the anticipated timeframe or achieve anticipated benefits.
- Ongoing generic erosion and revenue declines for Humira, which decreased by 35.9 percent globally.
- Unfavorable impacts related to acquired IPR&D and milestones expenses incurred year-to-date.
Topic velocity
Language versus prior quarter
M&ANew
CostNew
ChinaNew
MarginNew
RecordNew
iPhoneNew
Signal composition
What drove the EarnIQ score
Tone+20
Eps Beat+0
Guidance+15
New Signal+8
Miss Penalty+0
Qoq Improvement+8
Deflection Penalty+0